Sofinnova scores record-breaking exit

The $700m sale of medical device company CoreValve vindicates the venture firm’s strategy, proving wrong pundits who thought the firm the ‘last of the early stage Mohicans’, according to managing partner Antoine Papiernik. The deal is expected to generate more than 10x for the firm’s investors.